New Three-Drug cocktail takes on tough colorectal cancer

NCT ID NCT05959356

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding an immunotherapy drug (envafolimab) and a stronger chemotherapy mix (mFOLFOXIRI) to the standard treatment (cetuximab plus mFOLFOX6) can better control advanced left-sided colorectal cancer that has spread. About 198 people with a specific genetic type (RAS/BRAF wild-type, MSS) will be randomly assigned to one of the two treatment groups. The main goal is to see if the new combo delays cancer growth longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cetuximab, envafolimab, and a chemotherapy cocktail (mFOLFOXIRI)
What this could lead to: If successful, this combination could shrink more tumors and delay cancer growth better than current standard therapy for people with this specific type of colorectal cancer.
What could go wrong: This is an early phase 2 trial with only 198 participants, so results may not apply to everyone. The stronger chemo combo also carries higher risk of side effects like severe diarrhea, nerve damage, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Affiliated Cancer Hospital of Guizhou Medical University
RECRUITING

Guiyang, Guizhou, 550000, China
The First People's Hospital of Foshan
RECRUITING

Foshan, Guangdong, 528000, China
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.